Mayra Yebra, Shruti Bhargava, Avi Kumar, Adam M Burgoyne, Chih-Min Tang, Hyunho Yoon, Sudeep Banerjee, Joseph Aguilera, Thekla Cordes, Vipul Sheth, Sangkyu Noh, Rowan Ustoy, Sam Li, Sunil J Advani, Christopher L Corless, Michael C Heinrich, Razelle Kurzrock, Scott M Lippman, Paul T Fanta, Olivier Harismendy, Christian Metallo, Jason K Sicklick
PURPOSE: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract with mutant succinate dehydrogenase ( SDH ) subunits (A-D) comprising less than 7.5% (i.e. 150-200/year) of new cases annually in the United States. Contrary to GISTs harboring KIT or PDGFRA mutations, SDH -mutant GISTs affect adolescents/young adults, often metastasize, and are frequently resistant to tyrosine kinase inhibitors (TKIs). Lack of human models for any SDH- mutant tumors, including GIST, has limited molecular characterization and drug discovery...
August 23, 2021: Clinical Cancer Research